Polaris Pharmaceuticals-KY: Announcement of commitments made by the company during its stock listing application and subsequent execution status
Polaris Pharmaceuticals-KY announced on April 7, 2026, the commitments made during its stock listing application to the Taiwan Stock Exchange and their execution status. These commitments include disclosing information on new drug R&D, CDMO business, and funding needs in the prospectus, extending the centralized custody period for shares to three years, and removing provisions for independent directors to convene shareholder meetings. These have been implemented through prospectus disclosure, share submission, and amendment of the company's articles of association.
📋 Article Processing Timeline
- 📰 Published: April 7, 2026 at 09:00
- 🔍 Collected: April 8, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 11:30 (171h 30m after Collected)
1. Date of occurrence of the factual event: 2026/04/07
2. Company name: Polaris Pharmaceuticals Group Co., Ltd.
3. Relationship with the company (please enter 'the company' or 'subsidiary'): The company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence: In accordance with the letter Ref. No. 1111700849 from the Taiwan Stock Exchange Corporation dated March 25, 2022, the commitments made by the company during its initial stock listing are as follows:
(1) The following matters shall be disclosed in the special notes section of the prospectus:
1. The company's engagement in the research, development, and manufacturing of biologics new drugs, its main technical sources and patent protection, as well as the progress of various new drug R&D, market competitiveness, possible risks, and countermeasures.
2. Since 2019, the company has been engaged in contract development and manufacturing services (CDMO) for pharmaceuticals, including its development plan, competitive advantages, expected customer sources, possible risks, and countermeasures.
3. The company requires huge capital for both new drug R&D and CDMO business, including future capital needs and planning, possible working capital turnover risks, and countermeasures.
(2) The period for submitting shares to centralized custody shall be extended to three years, and one-third of the shares may be withdrawn after each full year from the start of listing and trading.
(3) The provision in Article 42.1 of the Articles of Association regarding independent directors convening shareholder meetings shall be deleted before listing.
6. Countermeasures:
As of 2026/04/07, the company's execution status is as follows:
(1) Relevant content has been appropriately disclosed in the prospectus for "Public Offering of New Shares for Initial Listing and Initial Stock Listing" published in May 2022, as detailed on the Market Observation Post System.
(2) The period for submitting shares to centralized custody has been extended to three years, and one-third of the shares may be withdrawn after each full year from the start of listing and trading.
(3) The amendment to the company's Articles of Association was resolved at the shareholder meeting on June 2, 2022.
7. Other matters to be specified (if the subject of the event or resolution is a public company or above, this material information also complies with the matters that have a significant impact on shareholders' equity or securities prices as stipulated in Article 7, Paragraph 9 of the Enforcement Rules of the Securities and Exchange Act): New drug development takes a long time, requires high investment, and is not guaranteed to succeed. These may expose investors to risks, and investors should make careful judgments and investments.
2. Company name: Polaris Pharmaceuticals Group Co., Ltd.
3. Relationship with the company (please enter 'the company' or 'subsidiary'): The company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence: In accordance with the letter Ref. No. 1111700849 from the Taiwan Stock Exchange Corporation dated March 25, 2022, the commitments made by the company during its initial stock listing are as follows:
(1) The following matters shall be disclosed in the special notes section of the prospectus:
1. The company's engagement in the research, development, and manufacturing of biologics new drugs, its main technical sources and patent protection, as well as the progress of various new drug R&D, market competitiveness, possible risks, and countermeasures.
2. Since 2019, the company has been engaged in contract development and manufacturing services (CDMO) for pharmaceuticals, including its development plan, competitive advantages, expected customer sources, possible risks, and countermeasures.
3. The company requires huge capital for both new drug R&D and CDMO business, including future capital needs and planning, possible working capital turnover risks, and countermeasures.
(2) The period for submitting shares to centralized custody shall be extended to three years, and one-third of the shares may be withdrawn after each full year from the start of listing and trading.
(3) The provision in Article 42.1 of the Articles of Association regarding independent directors convening shareholder meetings shall be deleted before listing.
6. Countermeasures:
As of 2026/04/07, the company's execution status is as follows:
(1) Relevant content has been appropriately disclosed in the prospectus for "Public Offering of New Shares for Initial Listing and Initial Stock Listing" published in May 2022, as detailed on the Market Observation Post System.
(2) The period for submitting shares to centralized custody has been extended to three years, and one-third of the shares may be withdrawn after each full year from the start of listing and trading.
(3) The amendment to the company's Articles of Association was resolved at the shareholder meeting on June 2, 2022.
7. Other matters to be specified (if the subject of the event or resolution is a public company or above, this material information also complies with the matters that have a significant impact on shareholders' equity or securities prices as stipulated in Article 7, Paragraph 9 of the Enforcement Rules of the Securities and Exchange Act): New drug development takes a long time, requires high investment, and is not guaranteed to succeed. These may expose investors to risks, and investors should make careful judgments and investments.